{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:21:39Z","timestamp":1791199299044,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1136\/ijgc-2022-004050","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T06:55:46Z","timestamp":1680504946000},"page":"623-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0878-2177","authenticated-orcid":false,"given":"Omar","family":"Touhami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"St-Gelais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-2648","authenticated-orcid":false,"given":"Michael","family":"Frumovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-004050_bb0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00404-015-3980-y","article-title":"Individual management of cervical cancer in pregnancy","volume":"293","author":"Hecking","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"10.1136\/ijgc-2022-004050_bb0015","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1067\/mob.2001.114867","article-title":"Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997","volume":"184","author":"Smith","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-004050_bb0020","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/00006254-200010000-00022","article-title":"Management of stage I cervical cancer in pregnancy","volume":"55","author":"Nguyen","year":"2000","journal-title":"Obstet Gynecol Surv"},{"key":"10.1136\/ijgc-2022-004050_bb0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/gyno.1998.5104","article-title":"Neuroendocrine small cell uterine cervix cancer in pregnancy: long-term survival following combined therapy","volume":"71","author":"Balderston","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004050_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4447-x","article-title":"Neuroendocrine carcinoma of the cervix: a systematic review of the literature","volume":"18","author":"Tempfer","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2022-004050_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1006\/gyno.2001.6201","article-title":"Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge","volume":"82","author":"Berm\u00fadez","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004050_bb0040","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00001813-199908000-00003","article-title":"Phase II trial of neoadjuvant chemotherapy in early-stage small cell cervical cancer","volume":"10","author":"Chang","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1136\/ijgc-2022-004050_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/annonc\/mdm465","article-title":"Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004050_bb0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdh061","article-title":"Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer","volume":"15","author":"Ramalingam","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004050_bb0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ygyno.2003.11.019","article-title":"Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma","volume":"92","author":"Tiersten","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004050_bb0060","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"The Lancet"},{"key":"10.1136\/ijgc-2022-004050_bb0065","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/ijgc-00009577-200507000-00011","volume":"15","author":"Tangjitgamol","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-004050_bb0070","first-page":"02270","article-title":"Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a neuroendocrine cervical tumor registry (nectur) study","author":"Frumovitz","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-004050_bb0075","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/ijgc-2019-000504","article-title":"Updates and management algorithm for neuroendocrine tumors of the uterine cervix","volume":"29","author":"Salvo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-004050_bb0080","doi-asserted-by":"crossref","first-page":"146","DOI":"10.21037\/atm.2018.04.03","article-title":"Advances on systemic treatment for lung neuroendocrine neoplasms","volume":"6","author":"Tsoukalas","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1136\/ijgc-2022-004050_bb0085","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/ijgc-2020-001649","article-title":"Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix","volume":"30","author":"Carroll","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-004050_bb0090","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-004050_bb0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1136\/ijgc-2022-004050_bb0100","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"Dna double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2022-004050_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s40661-017-0038-9","article-title":"Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report","volume":"4","author":"Paraghamian","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1136\/ijgc-2022-004050_bb0110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2016-0517","volume":"22","author":"Sharabi","year":"2017","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2022-004050_bb0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gore.2014.09.003","article-title":"Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation","volume":"10","author":"Lyons","year":"2014","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2022-004050_bb0120","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1078-0432.CCR-17-1872","article-title":"Targeting the MYCN\u2013PARP\u2013DNA damage response pathway in neuroendocrine prostate cancer","volume":"24","author":"Zhang","year":"2018","journal-title":"ClinCancer Res"},{"key":"10.1136\/ijgc-2022-004050_bb0125","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1158\/1078-0432.CCR-13-1975","article-title":"Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer","volume":"19","author":"Cardnell","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-004050_bb0130","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-004050_bb0135","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","article-title":"Development of PARP and immune-checkpoint inhibitor combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2022-004050_bb0140","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"Parp inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-004050_bb0145","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-004050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:28:53Z","timestamp":1753234133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24024381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1048891X24024381"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-004050","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-004050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}